However, it is surprising that only a few biological agents have been approved for veterinary medicine, including Frunevetmab and Bendinvetmab, anti-nerve growth factor antibodies approved for pain control in cats and dogs with osteoarthritis, respectively, and Lokivetab, an anti-interleukin-31 antibody for the treatment of pruritus and atopic dermatitis in dogs [25]. The gene discussed is NGF; the disease is osteoarthritis.